[
  {
    "ts": null,
    "headline": "Push UPs [Stocks] Vs Pull DOWNs [Retail Sales]",
    "summary": "This week's review and preview: The S&P 500 and Nasdaq showed bullish behavior, with the Dow Jones leading YTD gains at 4.7%, despite weak retail sales data. Read the full report here.",
    "url": "https://finnhub.io/api/news?id=c31df8fe8b2fca463f42ecc3799b980a278e8518addeb12c05a3ccf4f73c16b1",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739897952,
      "headline": "Push UPs [Stocks] Vs Pull DOWNs [Retail Sales]",
      "id": 132780121,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/948513030/image_948513030.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "This week's review and preview: The S&P 500 and Nasdaq showed bullish behavior, with the Dow Jones leading YTD gains at 4.7%, despite weak retail sales data. Read the full report here.",
      "url": "https://finnhub.io/api/news?id=c31df8fe8b2fca463f42ecc3799b980a278e8518addeb12c05a3ccf4f73c16b1"
    }
  },
  {
    "ts": null,
    "headline": "Cardiff Oncology: Pioneering RAS-Mutated Cancer Therapies With Onvansertib",
    "summary": "Cardiff Oncology: Pioneering RAS-Mutated Cancer Therapies With Onvansertib",
    "url": "https://finnhub.io/api/news?id=d8b1d0947d6754829b3abbb94e80bbadea9c4acd10a9ff06e54d3bb5d6eded71",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739870341,
      "headline": "Cardiff Oncology: Pioneering RAS-Mutated Cancer Therapies With Onvansertib",
      "id": 132767396,
      "image": "",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=d8b1d0947d6754829b3abbb94e80bbadea9c4acd10a9ff06e54d3bb5d6eded71"
    }
  },
  {
    "ts": null,
    "headline": "GSK's Strong Performance: Why I'm Upgrading To 'Strong Buy'",
    "summary": "GSK's revenue and EPS exceeded my expectations and those of analysts. Check out the reasons why I am upgrading GSK stock's rating from Buy to Strong Buy.",
    "url": "https://finnhub.io/api/news?id=79f9d082cf625de8b867702d2868dea83fc96c4cb55e6dce4daad22a8c0a5645",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739845293,
      "headline": "GSK's Strong Performance: Why I'm Upgrading To 'Strong Buy'",
      "id": 132765945,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/164210757/image_164210757.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "GSK's revenue and EPS exceeded my expectations and those of analysts. Check out the reasons why I am upgrading GSK stock's rating from Buy to Strong Buy.",
      "url": "https://finnhub.io/api/news?id=79f9d082cf625de8b867702d2868dea83fc96c4cb55e6dce4daad22a8c0a5645"
    }
  }
]